Incyte (NASDAQ: INCY)
Incyte Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Incyte Company Info
Incyte isn't the only drugmaker with a JAK inhibitor, but Jakafi's differentiation as a JAK1 and JAK2 inhibitor has helped the company stay on top of the treatment paradigm for myelofibrosis.
News & Analysis
Why Incyte Stock Was Tanking This Week
SPDR S&P Biotech ETF (XBI): How to Buy
Incyte Surpasses Q3 Revenue Estimates
Incyte delivered robust third-quarter revenue growth, surpassing expectations, despite increased operational costs.
These Are Billionaires’ Favorite Healthcare Stocks
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
3 Stocks the World's Smartest Investors Are Buying Hand Over Fist Right Now
Billionaire investors are backing up their trucks and loading up on these stocks.
2 Under-the-Radar Biotech Stocks to Buy in 2022
Don't overlook these two promising companies.
Facebook, Incyte Fall Despite the Nasdaq's Strong Wednesday Start
Find out what held these laggards back.
Is the PD-(L)1 Party Over After Incyte's FDA Rejection?
There's definitely already a crowded market for PD-1 and PD-L1 immunotherapies.
Valuation
Podcast Episodes
Here Are Biotech’s Big Pipeline Disappointments in 2018
A number of companies suffered setbacks this year.
Immuno-Oncology Suffered a Setback in 2018. What’s Next?
Checkpoint inhibitors remain top sellers, but it wasn’t all rosy news this year.
Earnings Transcripts
Incyte Corporation (INCY) Q3 2021 Earnings Call Transcript
INCY earnings call for the period ending September 30, 2021.
Incyte Corporation (INCY) Q2 2021 Earnings Call Transcript
INCY earnings call for the period ending June 30, 2021.
Incyte Corp (INCY) Q1 2021 Earnings Call Transcript
INCY earnings call for the period ending March 31, 2021.
Incyte Corp (INCY) Q4 2020 Earnings Call Transcript
INCY earnings call for the period ending February 9, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.